News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
Cash or Perish, Adherex Technologies Inc. Warns Investors
August 25, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
DURHAM – With just a little more than $10 million in cash, Adherex Technologies has warned investors that it could be forced to shut down operations without “substantial additional funds.”
Twitter
LinkedIn
Facebook
Email
Print
Bankruptcy
MORE ON THIS TOPIC
M&A
Merck KGaA inks $11B Bio-Techne buyout to expand into cell therapy production
June 26, 2026
·
2 min read
·
Nick Paul Taylor
Deals
Novartis, Antares stars align in cancer deal that could top $1.9B
June 24, 2026
·
2 min read
·
Gabrielle Masson
Deals
Lilly deepens relationship with China’s Abbisko for $1.9B biobucks
June 24, 2026
·
2 min read
·
Tristan Manalac
Podcast
AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more
June 24, 2026
·
1 min read
·
Jef Akst